MXPA98000603A - Use of ipriflavona to reduce the number of cells c - Google Patents
Use of ipriflavona to reduce the number of cells cInfo
- Publication number
- MXPA98000603A MXPA98000603A MXPA/A/1998/000603A MX9800603A MXPA98000603A MX PA98000603 A MXPA98000603 A MX PA98000603A MX 9800603 A MX9800603 A MX 9800603A MX PA98000603 A MXPA98000603 A MX PA98000603A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- lymphocytes
- treatment
- cytotoxic
- optionally
- Prior art date
Links
- SFBODOKJTYAUCM-UHFFFAOYSA-N 7-isopropoxyisoflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 210000004027 cells Anatomy 0.000 claims abstract description 32
- 210000004698 Lymphocytes Anatomy 0.000 claims abstract description 14
- 229960005431 ipriflavone Drugs 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 230000003247 decreasing Effects 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 230000001225 therapeutic Effects 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000000654 additive Substances 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims abstract description 4
- 230000001629 suppression Effects 0.000 claims abstract description 4
- 239000000969 carrier Substances 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- -1 infusion Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 2
- 230000001472 cytotoxic Effects 0.000 description 15
- 231100000433 cytotoxic Toxicity 0.000 description 15
- 210000001744 T-Lymphocytes Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 102000038129 antigens Human genes 0.000 description 3
- 108091007172 antigens Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001506 immunosuppresive Effects 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- 210000001541 Thymus Gland Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000007502 Anemia Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000735 allogeneic Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Abstract
The present invention relates to pharmaceutical compositions suitable for decreasing the number of CD8 + cells comprising a 7-isopropoxyisoflavone active ingredient in a mixture with suitable liquid, solid or inert carriers and optionally with customary therapeutic additives and auxiliary agents. The pharmaceutical compositions according to the invention are prepared by known methods and are suitable for the treatment of humans or animals under the condition where the selective suppression of CD8 + lymphocytes is desirable.
Description
USE OF IPRIFLAVONE TO REDUCE THE NUMBER OF CELLS CD8-I-
The invention relates to pharmaceutical compositions suitable for decreasing the number of CD8 + cells which contain 7-isopropoxyisoflavone. { IPRIFLAVONA) ees: active ingredient. IFRIFLAYGNA is an antioxicant agent; : rc t i ce known. Its preparation is described in the specifications of the Hungarian patent Nr. 152377 and 196981. It is known that the organism has two basic protective functions, the humoral and the immune-mediating mediating cells. Lae immune-response mediator cells are mainly directed against endogenous antigens in cells infected with a virus or with an intracellular parasite, cancer cells, chemically modified cells and foreign tissue. The immune response mediator cell is linked to lymphocytes (T lymphocytes) dependent on the thymus (cells that mature in the thymus). At the end of maturation of the maturation process, two types of T lymphocytes based on clearly differentiable subgroups by their superficial marks will be released to the periphery. CD4 + cells called helper cells are activated in the presence of exogenous antigens and help the immune response by increasing cytokine production. CD8 + cells called cytotoxic cells are activated by recognizing the endogenous antigen and then destroy the cells recognized as foreign by cytolysis. Aprcxin.adan.er.te 2/3 of the lymphocytes of the periphery are CD4 + and 1/3 CD8 +. The corresponding normal are CD4 + / CD8 + its ratio is 2: 1. (András Falus: Immunologi pages 111-138 TEMPUS ITC Bp./1993) The cytotoxic immunorrespueeta is a basic protective mechanism in case of intracellular infections because by means of the destruction of infected cells the possibility of reproduction of pathogenic agents is eliminated. In the same way, the destruction of cancer cells has a very important role. In these cases, the cytotoxic immune response serves to protect the integrity of the organism. It is also known of cases where, with respect to the organism, the cytotoxic immune response is undesirable or even harmful. In case of certain autoimmune diseases the cytotoxic reaction is directed towards the body's own cells, causing severe functional alterations as a result. A typical example of an immune-mediated disease by T cells is rheumatoid arthritis. The pathological cytotoxic reaction can be seen in the fall of certain plastic anemias and chronic active hepatitis. A rejection reaction after the transplantation of an organ or tissue is also based on the cytotoxic immune response. In case of a special organ transplant, for example bone marrow called "graft versus host" is also based on a cytotoxic reaction, in these cases, the ratio of CD4 + / CD8 + decreases, in certain cases it is reversed, which is mainly due to the increase of CD8 + cells and less the result of the decrease of CD4 + cells In the case of autoimmune diseases and rejection reactions after organ or tissue transplantation, it is a usual treatment procedure to moderate the immune response, up to certain cases reduce it drastically (Immunosuppressive treatment) Immunosuppressive treatments cause not only a decrease in the number of T lymphocytes but also an effect against the normalization of the ratio of CD4 + / CD8 + cells In the case of an allogeneic bone marrow transplant, which does not contain CD8 + cells "" graft versus host "in the reaction can be observed significantly amente fewer numbers. Therefore, in the aforementioned diseases, a therapy that specifically decreases the number of CE5 + cells can be advantageous. Based on the aforementioned theoretical considerations and practical experiences, we examined the type of effects that ipriflavone treatment has on the T lymphocytes responsible for the cell-mediated immunoresponse and on the number of cytotoxic CD4 + and CD8 + helper cells. To separate a certain type of lymphocyte and its subgroups, we used flow cytometry. In a clinical analysis, the absolute count of lymphocytes and the change in certain subpopulations of lymphocytes were studied in 60 patients taking a daily dose of 400 mg of ipriflavone. In 51 patients, a mild or moderate decrease in the absolute lymphocyte count was observed. The mean absolute count of lymphocytes of patients was 0.85xl09 / l (range 0.25-0.89) after treatment. (normal range: 0.9-3.22x10 / l). In 9 patients, the mean absolute count of lymphocytes was found in the normal range of 1.84x10 / l. In 51 patients with lymphopenia the decrease was characteristic only by so-called T lymphocytes and among them pronounced major for the CD8- subpopulation. The CD8 + count was 0.08xl09 / l (range 0.02-0.231, the table shows a cell count reduction means iva taking into account that the standard range is D.3-1.44xl09 / l- In the 9 patients that showed a Normal lymphocyte count, the average CD8 + count was 10.43xlC9''l (range of 0.28-0.64). Although this value is within the normal range falls in its lower quarter, this discovery supports the selective nature of the effect. that under the ipriflavone treatment, the number of T lymphocytes decreased and averaged 66.6%, Considering the cytotoxic CD4 + and CD8 + auxiliary subgroups, the average decrease was significantly different, Compared with the 50% reduction of CD4 + helper cells, the decrease of cytotoxic CD8 cells were 77% .The CD4 + / CD8 ratio characterizes a different number of CD4 + CD8 + cells, the change ratio was 5: 1 in the treatment of ipriflavone, the decrease in the number of T lymphocytes, c CD4 + helper cells and CD8 + cytotoxic cells and the basic change in their relationships was considerable in two aspects. In the course of traditional immunosuppressive treatments, a sminucicr was observed. in the number of cells smaller than the one experienced, in the case of ipriflavone. Another significant difference is the steeper decrease in the number of CD8 + cytotoxic cells compared to the number of CD4 + helper cells. Based on the results, it can be assumed that ipriflavone is able to decrease or specifically inhibit the cytotoxic reaction. The object of the invention is a pharmaceutical composition suitable for decreasing the number of CD8 + cells comprising as an active ingredient the 7- isopropoxyisoflavone mixed with a suitable solid or inert liquid carrier and optionally with the usual additives and therapeutic aids. The aforementioned composition can be used for the treatment of humans or animals, being a condition where the selective suppression of CD8 + lymphocytes is desirable. The compositions according to the invention can be prepared in the form of injection, infusion, capsules, tablets, solution, syrup, transdermal preparation, etc. by methods known per se. In diseases or states of condition where the inhibition of the cytotoxic reaction has a therapeutic value, they are quite different in their nature, appearance and courses of the disease. Therefore, the dose has to be determined in knowledge of the diagnosis, initial number of lymphocytes and the ratio of CD4 + / CDB + cells.
Claims (4)
1. A pharmaceutical composition suitable for decreasing the number of CD8 + cells comprising a therapeutically active amount of 7-isopropoxy isoflavone as an active ingredient in a mixture with suitable liquid, inert solid or inert vehicles and optionally with usual therapeutic additives and auxiliary agents.
2 . A composition according to claim 1 in the form of an injection, infusion, capsule, tablet, solution, syrup or brindermal preparation.
3. Use of 7-isopropoxy i sof lavone for the production of a medicament for the treatment of clinical conditions where the selective suppression of CD8 + lymphocytes is desirable.
4. Method of treatment of a human or animal in conditions where the selective suppression of CD8 + lymphocytes is desirable, which comprises. the step of administering an effective amount of 7-isopropoxy isoflavone in a mixture with a suitable liquid, solid or inert carrier and optionally with the usual therapeutic additives and auxiliary agents.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9502198A HU9502198D0 (en) | 1995-07-21 | 1995-07-21 | Novel indication |
| HUP9502198 | 1995-07-21 | ||
| PCT/HU1996/000038 WO1997003664A1 (en) | 1995-07-21 | 1996-07-16 | Use of ipriflavone to reduce the number of cd8+ cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MXPA98000603A true MXPA98000603A (en) | 1998-04-01 |
| MX9800603A MX9800603A (en) | 1998-04-30 |
Family
ID=10987063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9800603A MX9800603A (en) | 1995-07-21 | 1996-07-16 | Use of ipriflavone to reduce the number of cd8+ cells. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0841915A1 (en) |
| JP (1) | JP2001503371A (en) |
| KR (1) | KR19990028933A (en) |
| CN (1) | CN1191483A (en) |
| AR (1) | AR002905A1 (en) |
| AU (1) | AU6367096A (en) |
| BG (1) | BG102182A (en) |
| BR (1) | BR9610187A (en) |
| CA (1) | CA2227421A1 (en) |
| CZ (1) | CZ2798A3 (en) |
| EA (1) | EA199800146A1 (en) |
| EE (1) | EE9800020A (en) |
| HR (1) | HRP960345A2 (en) |
| HU (1) | HU9502198D0 (en) |
| IL (1) | IL122751A0 (en) |
| MX (1) | MX9800603A (en) |
| NO (1) | NO980127D0 (en) |
| PL (1) | PL324460A1 (en) |
| SK (1) | SK3298A3 (en) |
| WO (1) | WO1997003664A1 (en) |
| YU (1) | YU42796A (en) |
| ZA (1) | ZA966079B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1241079B (en) * | 1990-03-23 | 1993-12-29 | Chiesi Farma Spa | PHARMACEUTICAL COMPOSITIONS CONTAINING IPRIFLAVONE, PROCEDURE FOR THEIR PREPARATION AND RELATED THERAPEUTIC USE |
| HU212932B (en) * | 1993-08-02 | 1996-12-30 | Chinoin Gyogyszer Es Vegyeszet | Parmaceutical composition containing ipriflavone, hydroxyapatit and tricalciumphosphate for treating lack of bones and process for producing the composition |
-
1995
- 1995-07-21 HU HU9502198A patent/HU9502198D0/en unknown
-
1996
- 1996-07-16 KR KR1019980700235A patent/KR19990028933A/en not_active Application Discontinuation
- 1996-07-16 MX MX9800603A patent/MX9800603A/en unknown
- 1996-07-16 JP JP50646497A patent/JP2001503371A/en active Pending
- 1996-07-16 EE EE9800020A patent/EE9800020A/en unknown
- 1996-07-16 CA CA002227421A patent/CA2227421A1/en not_active Abandoned
- 1996-07-16 CZ CZ9827A patent/CZ2798A3/en unknown
- 1996-07-16 EA EA199800146A patent/EA199800146A1/en unknown
- 1996-07-16 CN CN96195722A patent/CN1191483A/en active Pending
- 1996-07-16 SK SK32-98A patent/SK3298A3/en unknown
- 1996-07-16 EP EP96923004A patent/EP0841915A1/en not_active Withdrawn
- 1996-07-16 AU AU63670/96A patent/AU6367096A/en not_active Abandoned
- 1996-07-16 PL PL96324460A patent/PL324460A1/en unknown
- 1996-07-16 WO PCT/HU1996/000038 patent/WO1997003664A1/en not_active Application Discontinuation
- 1996-07-16 BR BR9610187A patent/BR9610187A/en not_active Application Discontinuation
- 1996-07-16 IL IL12275196A patent/IL122751A0/en unknown
- 1996-07-17 ZA ZA9606079A patent/ZA966079B/en unknown
- 1996-07-18 HR HRP9502198A patent/HRP960345A2/en not_active Application Discontinuation
- 1996-07-19 YU YU42796A patent/YU42796A/en unknown
- 1996-07-22 AR ARP960103677A patent/AR002905A1/en unknown
-
1998
- 1998-01-12 NO NO980127A patent/NO980127D0/en unknown
- 1998-01-14 BG BG102182A patent/BG102182A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006320162B2 (en) | Use of high-dose oxazaphosphorine drugs for treating immune disorders | |
| EA003142B1 (en) | Pharmaceutical composition with an antidepressive effect use thereof and method for treating | |
| JP2002523378A (en) | Activation and protection of T-cells (CD4 + and CD8 +) using H2-receptor agonists and other T-cell activating agents | |
| US20180185300A1 (en) | Cannabidiol for the prevention and treatment of graft-versus-host disease | |
| JP2003505348A (en) | Activation and protection of cytotoxic lymphocytes using reactive oxygen metabolite inhibitors | |
| Oka et al. | Immunosuppression in organ transplantation | |
| JPH10139670A (en) | Interleukin 12 inducer and pharmaceutical composition | |
| JP2706371B2 (en) | Auxiliary agent for cancer treatment and kit using the same | |
| EP0303687B1 (en) | Compositions for enhancing adcc therapy | |
| EP0081882B1 (en) | Medicine having transplant rejection and/or immunological inflammation inhibiting activities, as well as a method for inhibiting transplant rejection and/or immunological inflammation | |
| Klein | Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine | |
| MXPA98000603A (en) | Use of ipriflavona to reduce the number of cells c | |
| US3803319A (en) | Treating hyperlipemia with isatin | |
| WO1997003664A1 (en) | Use of ipriflavone to reduce the number of cd8+ cells | |
| CN113194936A (en) | Composition for preventing and treating transplant rejection or transplant rejection disease comprising novel compound and calcineurin inhibitor | |
| EP0522001B1 (en) | Supportive use of linomide (r) | |
| KR100681626B1 (en) | Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases | |
| US3679793A (en) | Method of raising the white blood cell count | |
| JPH06135836A (en) | Inducer for contra-suppressor cell | |
| SK76696A3 (en) | Pentoxifyllin allone or in combination with corticosteroid | |
| Rosenfeld et al. | Ex vivo purging of allogeneic marrow with L-leucyl-L-leucine methyl ester: a phase I study | |
| JP2928608B2 (en) | Insulin-dependent diabetes mellitus preventive or therapeutic agent | |
| EP0216072B1 (en) | Use of dibenz[cd,f]indole derivatives in the prevention of alcohol abuse | |
| CN114028374A (en) | Application of dimethyl fumarate in preparation of medicines for protecting pancreatic beta cell function | |
| Patchen et al. | Hemopoietic and survival-enhancing effects of xerosin II, ribavarin, bru-pel, and ampligen |